Ó³»­´«Ã½

Zeina Reda Al Sayed is a postdoctoral researcher in the Cardiovascular Disease Initiative at the Ó³»­´«Ã½ of MIT and Harvard, where she focuses on studying heart failure, particularly metabolic dysfunctions associated with or leading to cardiomyopathies. Her work involves running CRISPR screens in iPSC-derived cardiomyocytes in an attempt to find a therapy for heart failure. Al Sayed is supported by an AHA Postdoctoral Fellowship. 

Al Sayed earned her Ph.D. in biomedical science, specializing in cardiovascular physiopathology at Nantes University (Institut de Thorax, France), where she conducted research on cardiac arrhythmia and channelopathies under the guidance of Patricia Lemarchand and Nathalie Gaborit. She later joined Jean-Sebastien Hulot's lab at the Paris Cardiovascular Research Center to study drug-induced long QT syndrome (acquired arrhythmia) as part of a Leducq program led by Peter Schwartz and Joseph C. Wu.